Metabolic researcher Nick Norwitz has raised concerns about what he describes as selective data presentation in Dr. Peter Attia’s recent newsletter discussing statins and GLP-1 hormone levels.
According to Norwitz’s recent YouTube video, the controversy centers on a study published in Cell Metabolism that Norwitz claims Attia addressed without including its most significant findings.
Norwitz states that the study in question examined 40 participants who received either atorvastatin (the highest-grossing pharmaceutical in history at over $150 billion in sales) or a control intervention.
The research showed that statin users experienced approximately 50% reduction in GLP-1 levels, alongside worsening glycemic markers and increased insulin resistance.
Norwitz alleges that while Attia’s newsletter included other panels from the study’s figures showing cholesterol reductions, it conspicuously omitted the central graph displaying the dramatic GLP-1 decrease.
“When the most important result disappears, that’s not nuance and accuracy. It’s curation,” Norwitz stated.
The timing of Attia’s newsletter also raised questions. Norwitz notes that he had extensively covered this two-year-old paper across multiple platforms and tagged Attia directly. The paper subsequently jumped to the top of Cell Metabolism’s most-read list.
Less than two weeks later, Attia’s response appeared, though it did not mention Norwitz by name.
Beyond the omission, Norwitz identifies what he considers flaws in Attia’s analysis. He takes issue with comparing baseline GLP-1 levels to post-meal spikes, calling it a “biological category error.”
Norwitz draws an analogy to fasting insulin levels, noting that no credible researcher would dismiss their importance simply because insulin rises higher after eating.
Norwitz emphasizes that he has never claimed statins should never be used based on this research. Instead, he argues that a 50% reduction in a central metabolic hormone, paired with worsening glycemic control, deserves acknowledgment in clinical conversations.
He suggests the study identifies plausible mechanisms that could inform risk mitigation strategies, such as targeted bile acid supplementation.
The researcher outlines three principles for evaluating such findings. First, absence of evidence is not evidence of absence, and the burden of proof for widely prescribed medications should lie with establishing safety.
Second, research incentive structures favor population-level studies over precision medicine, potentially overlooking individual variability in treatment response. Third, withholding information from patients, whether intentionally or through oversight, erodes trust in medical guidance.
Norwitz, who describes himself as new to public science communication, frames this as part of his learning process in navigating disagreement within the medical community. He points to previous productive conversations with researchers across ideological spectrums, from carnivore advocates to plant-based nutrition proponents, as examples of his commitment to substantive dialogue.
Norwitz emphasizes his goal is not to manufacture controversy but to advocate for transparency in discussing research findings that might inform patient care. He stated: “It is me responding directly and transparently to arguments Peter has chosen to make publicly in response to my work.”
